-

02:30:00 AM

INMB Stock News

INMB - INmune Bio Inc

01/25/23 7:45 AM

Nasdaq : INMB

clinical triallow float

INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, in collaboration with Professor Armando Villalta, Ph.D. of

RHEA-AI

neutral

12/22/22 8:00 AM

Nasdaq : INMB

low float

INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the

RHEA-AI

neutral

12/08/22 8:00 AM

Nasdaq : INMB

low float

INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™

INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease will present data from UK patients with MDS or

RHEA-AI

neutral

12/06/22 4:00 PM

Nasdaq : INMB

low float

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer

Neutralizing soluble TNF with INB03™ overcomes resistance to trastuzumab-deruxtecan in MUC4 expressing HER2+breast cancer. Combination therapy of INB03™ and trastuzumab-deruxtecan presented at the 45th annual San Antonio Breast Cancer Symposium today Boca Raton, Florida, Dec. 06, 2022 (GLOBE

RHEA-AI

positive

11/29/22 8:00 AM

Nasdaq : INMB

clinical triallow float

INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology

RHEA-AI

neutral

11/14/22 9:00 AM

Nasdaq : INMB

clinical triallow float

INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces that Health Canada has issued the Company a

RHEA-AI

neutral

11/02/22 4:00 PM

Nasdaq : INMB

low float

INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight

RHEA-AI

neutral

10/26/22 8:10 AM

Nasdaq : INMB

conferencesearningslow float

INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to

RHEA-AI

neutral

10/19/22 8:00 AM

Nasdaq : INMB

low float

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that

RHEA-AI

neutral

09/07/22 9:00 AM

Nasdaq : INMB

conferenceslow float

INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare Conference

INmune Bio (NASDAQ: INMB), a clinical- stage immunology company focused on developing treatments that harness the patient’s immune system to fight disease, announced today that RJ Tesi, M.D., Chief Executive Officer will present a corporate

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

INMB Data

IndustryResearch and Development in Biotechnology
Websitewww.inmunebio.com
Security nameINmune Bio Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code2836
Employees10
Tags
- Medical Specialties
- Biotechnology
- Health Technology

About INmune Bio Inc

INmune Bio, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.